http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 25 Aug 2026 08:28:16 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Kardigan+Inc+%28KARD%29+PT+Lowered+to+%2446+at+JPMorgan/26971276.html JPMorgan analyst Anupam Rama lowered the price target on Kardigan Inc (NASDAQ: KARD) to $46.00 (from $51.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Kardigan+Inc+%28KARD%29+PT+Lowered+to+%2446+at+JPMorgan/26971276.html Tue, 25 Aug 2026 08:28:16 -0400 KARD http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+GIANAKAKOS+ANASTASIOS/26923119.html si-local-file:///var/storage/secattach/20260813/26923119.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+GIANAKAKOS+ANASTASIOS/26923119.html Thu, 13 Aug 2026 19:07:00 -0400 KARD O.71573107 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+GIANAKAKOS+ANASTASIOS/26923119.html si-local-file:///var/storage/secattach/20260813/26923119.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+GIANAKAKOS+ANASTASIOS/26923119.html Thu, 13 Aug 2026 19:07:00 -0400 KARD O.71573107 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Edelberg+Jay/26923033.html si-local-file:///var/storage/secattach/20260813/26923033.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Edelberg+Jay/26923033.html Thu, 13 Aug 2026 18:23:00 -0400 KARD O.71573107 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Edelberg+Jay/26923033.html si-local-file:///var/storage/secattach/20260813/26923033.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Edelberg+Jay/26923033.html Thu, 13 Aug 2026 18:23:00 -0400 KARD O.71573107 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kardigan%2C+Inc.++++++++++++For%3A+Jun+30/26901307.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260811/A52ZK22FZZ2RH9Z2229G2ZYKMTBIZZ22XI82">http://archive.fast-edgar.com/20260811/A52ZK22FZZ2RH9Z2229G2ZYKMTBIZZ22XI82</a></p> <p> Filed on: August 11, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kardigan%2C+Inc.++++++++++++For%3A+Jun+30/26901307.html Tue, 11 Aug 2026 07:11:00 -0400 KARD O.71573107 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kardigan%2C+Inc.++++++++++++For%3A+Jun+30/26901307.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260811/A52ZK22FZZ2RH9Z2229G2ZYKMTBIZZ22XI82">http://archive.fast-edgar.com/20260811/A52ZK22FZZ2RH9Z2229G2ZYKMTBIZZ22XI82</a></p> <p> Filed on: August 11, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kardigan%2C+Inc.++++++++++++For%3A+Jun+30/26901307.html Tue, 11 Aug 2026 07:11:00 -0400 KARD O.71573107 http://www.streetinsider.com/Press+Releases/Kardigan+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Updates/26901065.html <p class="bwalignc"> <i>Continued to advance the development of three late-stage programs, supported by the Prolaio platform, aimed at addressing cardiovascular diseases where no approved treatments exist</i> </p><p class="bwalignc"> <i>Danicamtiv KINSHIP-DCM Phase 3 Cohort 1 enrollment now underway; Phase 2b topline data expected 1H 2027</i> </p><p class="bwalignc"> <i>Strong cash position of $661 million following recent IPO extends runway through multiple data readouts and initiation of Phase 3 clinical trials</i> </p> <p> SOUTH SAN FRANCISCO, Calif. &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan” or “the Company”), a clinical-stage precision therapeutics company developing medicines that target the root causes of cardiovascular diseases with no approved treatments, http://www.streetinsider.com/Press+Releases/Kardigan+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Updates/26901065.html Tue, 11 Aug 2026 07:00:00 -0400 KARD O.71573107 http://www.streetinsider.com/Press+Releases/Kardigan+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Updates/26901065.html <p class="bwalignc"> <i>Continued to advance the development of three late-stage programs, supported by the Prolaio platform, aimed at addressing cardiovascular diseases where no approved treatments exist</i> </p><p class="bwalignc"> <i>Danicamtiv KINSHIP-DCM Phase 3 Cohort 1 enrollment now underway; Phase 2b topline data expected 1H 2027</i> </p><p class="bwalignc"> <i>Strong cash position of $661 million following recent IPO extends runway through multiple data readouts and initiation of Phase 3 clinical trials</i> </p> <p> SOUTH SAN FRANCISCO, Calif. &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan” or “the Company”), a clinical-stage precision therapeutics company developing medicines that target the root causes of cardiovascular diseases with no approved treatments, http://www.streetinsider.com/Press+Releases/Kardigan+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Updates/26901065.html Tue, 11 Aug 2026 07:00:00 -0400 KARD O.71573107 http://www.streetinsider.com/Business+Wire/Kardigan+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Updates/26901065.html <p class="bwalignc"> <i>Continued to advance the development of three late-stage programs, supported by the Prolaio platform, aimed at addressing cardiovascular diseases where no approved treatments exist</i> </p><p class="bwalignc"> <i>Danicamtiv KINSHIP-DCM Phase 3 Cohort 1 enrollment now underway; Phase 2b topline data expected 1H 2027</i> </p><p class="bwalignc"> <i>Strong cash position of $661 million following recent IPO extends runway through multiple data readouts and initiation of Phase 3 clinical trials</i> </p> <p> SOUTH SAN FRANCISCO, Calif. &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan” or “the Company”), a clinical-stage precision therapeutics company developing medicines that target the root causes of cardiovascular diseases with no approved treatments, http://www.streetinsider.com/Business+Wire/Kardigan+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Updates/26901065.html Tue, 11 Aug 2026 07:00:00 -0400 KARD O.71573107 http://www.streetinsider.com/Business+Wire/Kardigan+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Updates/26901065.html <p class="bwalignc"> <i>Continued to advance the development of three late-stage programs, supported by the Prolaio platform, aimed at addressing cardiovascular diseases where no approved treatments exist</i> </p><p class="bwalignc"> <i>Danicamtiv KINSHIP-DCM Phase 3 Cohort 1 enrollment now underway; Phase 2b topline data expected 1H 2027</i> </p><p class="bwalignc"> <i>Strong cash position of $661 million following recent IPO extends runway through multiple data readouts and initiation of Phase 3 clinical trials</i> </p> <p> SOUTH SAN FRANCISCO, Calif. &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Kardigan™, Inc. (Nasdaq: KARD) (“Kardigan” or “the Company”), a clinical-stage precision therapeutics company developing medicines that target the root causes of cardiovascular diseases with no approved treatments, http://www.streetinsider.com/Business+Wire/Kardigan+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Updates/26901065.html Tue, 11 Aug 2026 07:00:00 -0400 KARD O.71573107 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kardigan%2C+Inc.++++++++++++For%3A+Aug+11/26901143.html si-local-file:///var/storage/secattach/20260811/26901143.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kardigan%2C+Inc.++++++++++++For%3A+Aug+11/26901143.html Tue, 11 Aug 2026 07:00:00 -0400 KARD O.71573107 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kardigan%2C+Inc.++++++++++++For%3A+Aug+11/26901143.html si-local-file:///var/storage/secattach/20260811/26901143.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kardigan%2C+Inc.++++++++++++For%3A+Aug+11/26901143.html Tue, 11 Aug 2026 07:00:00 -0400 KARD O.71573107 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+FMR+LLC/26889378.html si-local-file:///var/storage/secattach/20260807/26889378.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+FMR+LLC/26889378.html Fri, 07 Aug 2026 11:17:00 -0400 KARD O.71573107 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+FMR+LLC/26889378.html si-local-file:///var/storage/secattach/20260807/26889378.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+FMR+LLC/26889378.html Fri, 07 Aug 2026 11:17:00 -0400 KARD O.71573107 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+FMR+LLC/26881478.html si-local-file:///var/storage/secattach/20260806/26881478.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+FMR+LLC/26881478.html Thu, 06 Aug 2026 10:48:00 -0400 KARD O.71573107 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+FMR+LLC/26881478.html si-local-file:///var/storage/secattach/20260806/26881478.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Kardigan%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+FMR+LLC/26881478.html Thu, 06 Aug 2026 10:48:00 -0400 KARD O.71573107 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kardigan%2C+Inc.++++++++++++For%3A+Jun+17++Filed+by%3A+EDELMAN+JOSEPH/26763006.html si-local-file:///var/storage/secattach/20260713/26763006.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Kardigan%2C+Inc.++++++++++++For%3A+Jun+17++Filed+by%3A+EDELMAN+JOSEPH/26763006.html Mon, 13 Jul 2026 16:45:00 -0400 KARD http://www.streetinsider.com/New+Coverage/Leerink+Starts+Kardigan+Inc+%28KARD%29+at+Outperform/26759195.html <p>Leerink initiates coverage on Kardigan Inc (NASDAQ: KARD) with a Outperform rating and a price target of $37.00.</p> <p>For an analyst ratings summary and ratings history on Kardigan Inc <a href="http://www.streetinsider.com/rating_history.php?q=KARD">click here</a>. For more ratings news on Kardigan Inc <a href="http://www.streetinsider.com/stock_lookup_news.php?q=KARD&amp;type=analyst">click here</a>.</p> <p>Shares of Kardigan Inc closed at $24.64 yesterday.</p> http://www.streetinsider.com/New+Coverage/Leerink+Starts+Kardigan+Inc+%28KARD%29+at+Outperform/26759195.html Mon, 13 Jul 2026 06:04:08 -0400 KARD http://www.streetinsider.com/New+Coverage/TD+Cowen+Starts+Kardigan+Inc+%28KARD%29+at+Buy/26758969.html <p>TD Cowen analyst Ritu Baral initiates coverage on Kardigan Inc (NASDAQ: KARD) with a Buy rating and a price target of $46.00.</p><p>The analyst comments "We are initiating on KARD with a Buy and $46 PT. KARD's late-stage precision cardiology assets target the root causes of CVDs that have no approved treatments. We are bullish on lead asset Ph2b/3 dani' in gDCM; Ph2b/3 ATA in mod CAVS and Ph2b TLA in ASH represent 2 addt'l derisked shots on goal. We think 1H27 topline Ph2b data for all 3 assets will be positive, and support progression into Ph3."</p><p>For an analyst ratings summary http://www.streetinsider.com/New+Coverage/TD+Cowen+Starts+Kardigan+Inc+%28KARD%29+at+Buy/26758969.html Mon, 13 Jul 2026 05:30:11 -0400 KARD http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Starts+Kardigan+Inc+%28KARD%29+at+Buy/26758969.html <p>TD Cowen analyst Ritu Baral initiates coverage on Kardigan Inc (NASDAQ: KARD) with a Buy rating and a price target of $46.00.</p><p>The analyst comments "We are initiating on KARD with a Buy and $46 PT. KARD's late-stage precision cardiology assets target the root causes of CVDs that have no approved treatments. We are bullish on lead asset Ph2b/3 dani' in gDCM; Ph2b/3 ATA in mod CAVS and Ph2b TLA in ASH represent 2 addt'l derisked shots on goal. We think 1H27 topline Ph2b data for all 3 assets will be positive, and support progression into Ph3."</p><p>For an analyst ratings summary http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Starts+Kardigan+Inc+%28KARD%29+at+Buy/26758969.html Mon, 13 Jul 2026 05:30:11 -0400 KARD http://www.streetinsider.com/New+Coverage/Jefferies+Starts+Kardigan+Inc+%28KARD%29+at+Buy/26758716.html <p>Jefferies analyst Dennis Ding initiates coverage on Kardigan Inc (NASDAQ: KARD) with a Buy rating and a price target of $40.00.</p><p>The analyst comments: “We see value creating catalysts for KARD's three specialty cardiology programs in H1:27. At $2B cap, funded into 2028, and led by the ex-MYOK team, there's upside should even one of them work given our view each can be a blockbuster $1-3B drug and w/o the need for a large Phase III CVOT. Early data looks promising as biomarkers are trending in the right direction, and we need longer term data to confirm efficacy and also safety. http://www.streetinsider.com/New+Coverage/Jefferies+Starts+Kardigan+Inc+%28KARD%29+at+Buy/26758716.html Mon, 13 Jul 2026 02:14:26 -0400 KARD http://www.streetinsider.com/Analyst+Comments/Jefferies+Starts+Kardigan+Inc+%28KARD%29+at+Buy/26758716.html <p>Jefferies analyst Dennis Ding initiates coverage on Kardigan Inc (NASDAQ: KARD) with a Buy rating and a price target of $40.00.</p><p>The analyst comments: “We see value creating catalysts for KARD's three specialty cardiology programs in H1:27. At $2B cap, funded into 2028, and led by the ex-MYOK team, there's upside should even one of them work given our view each can be a blockbuster $1-3B drug and w/o the need for a large Phase III CVOT. Early data looks promising as biomarkers are trending in the right direction, and we need longer term data to confirm efficacy and also safety. http://www.streetinsider.com/Analyst+Comments/Jefferies+Starts+Kardigan+Inc+%28KARD%29+at+Buy/26758716.html Mon, 13 Jul 2026 02:14:26 -0400 KARD http://www.streetinsider.com/New+Coverage/JPMorgan+Starts+Kardigan+Inc+%28KARD%29+at+Overweight/26758714.html <p>JPMorgan analyst Anupam Rama initiates coverage on Kardigan Inc (NASDAQ: KARD) with a Overweight rating and a price target of $51.00.</p><p>The analyst comments: “We are initiating coverage on Kardigan (KARD) with an Overweight rating and a December 2027 price target of $51. We see each of Kardigan’s mid-stage cardiovascular pipeline assets – danicamtiv (genetic dilated cardiomyopathy; DCM) / ataciguat (moderate calcific aortic valve stenosis; CAVS) / tonlamarsen (acute severe hypertension; ASH) – as having: 1) early de-risking proof-ofconcept data (though conservatively we model probability of success (POS) as <50% for each), 2) value-creating potential in the next ~6-12 month timeframe http://www.streetinsider.com/New+Coverage/JPMorgan+Starts+Kardigan+Inc+%28KARD%29+at+Overweight/26758714.html Mon, 13 Jul 2026 02:11:55 -0400 KARD http://www.streetinsider.com/Analyst+Comments/JPMorgan+Starts+Kardigan+Inc+%28KARD%29+at+Overweight/26758714.html <p>JPMorgan analyst Anupam Rama initiates coverage on Kardigan Inc (NASDAQ: KARD) with a Overweight rating and a price target of $51.00.</p><p>The analyst comments: “We are initiating coverage on Kardigan (KARD) with an Overweight rating and a December 2027 price target of $51. We see each of Kardigan’s mid-stage cardiovascular pipeline assets – danicamtiv (genetic dilated cardiomyopathy; DCM) / ataciguat (moderate calcific aortic valve stenosis; CAVS) / tonlamarsen (acute severe hypertension; ASH) – as having: 1) early de-risking proof-ofconcept data (though conservatively we model probability of success (POS) as <50% for each), 2) value-creating potential in the next ~6-12 month timeframe http://www.streetinsider.com/Analyst+Comments/JPMorgan+Starts+Kardigan+Inc+%28KARD%29+at+Overweight/26758714.html Mon, 13 Jul 2026 02:11:55 -0400 KARD